Second-order map
Exploratory — reasoned, hypothetical relationships for research, not investment advice.
- LLYCatalyst
Eli Lilly and Company
Q2 2026 GLP-1 results and first full-quarter read on oral orforglipron (Foundayo) reframe oral delivery as the primary axis of GLP-1 competition, forcing rivals to activate new NDA and formulation workflows
- CERTSpotlight subject
Certara, Inc.
Biosimulation and model-informed regulatory science bottleneck every competing oral/next-gen GLP-1 filer must activate; expedited pharmacometrics submission service is structurally more valuable when many sponsors file concurrently
- SLP
Simulations Plus, Inc.
Adjacent PBPK/biosimulation and formulation-modeling vendor; a broad wave of oral GLP-1 formulation-optimization work could lift demand across the whole model-informed drug development category, not just one provider
- SDGR
Schrodinger, Inc.
Computational molecular design platform; if oral delivery becomes the competitive axis, upstream in-silico optimization of orally bioavailable small molecules becomes a differentiator sponsors invest in earlier
- MEDP
Medpace Holdings, Inc.
CRO that runs the actual clinical programs behind those NDAs; a surge of concurrent oral GLP-1 filings implies more trials needing execution capacity
- IQV
IQVIA Holdings Inc.
Regulatory-affairs, analytics and clinical-data infrastructure; concurrent multi-sponsor filing activity increases demand for submission and real-world evidence services around it
- CTLT
Catalent, Inc.
Oral drug-delivery and formulation/manufacturing specialist; if competition shifts from injectable to oral GLP-1s, demand for oral-formulation development and fill-finish capacity is an imminent operational beneficiary
Specialty oral-dosage excipient supplier
Oral formulation optimization can raise demand for functional excipients and coatings; if a supplier holds meaningful share in oral solid-dose excipients it could see order flow, stated as hypothesis
- DHR
Danaher Corporation
Bioprocess and analytical instrumentation arm supplies characterization tools; a broader wave of new formulation and NDA work could raise consumable and instrument pull-through
- WST
West Pharmaceutical Services, Inc.
Containment/delivery components; a shift toward oral could reshuffle its injectable-component demand while packaging needs for oral solid-dose products emerge as an offsetting lateral effect
- TXG
10x Genomics, Inc.
Not a direct GLP-1 supplier, but intensified next-generation formulation competition can push sponsors toward deeper mechanistic and single-cell profiling to differentiate assets, a more lateral research-tools demand hypothesis
- TMO
Thermo Fisher Scientific Inc.
Broad research-reagent and CDMO backbone; a wider next-gen GLP-1 development wave diffuses into generalized lab-consumable and outsourced-development demand
- A
Agilent Technologies, Inc.
Analytical instrumentation for formulation characterization and QC; more concurrent oral formulation programs implies more analytical method-development workload
- BRKR
Bruker Corporation
Structural and mass-spec analytics used in characterizing complex oral formulations; a lateral beneficiary if characterization intensity rises across many parallel programs
Take it further
Copy the analysis below into your own AI tool to pressure-test the reasoning and push it further.
Today's crowd trade is straightforward — investors will be closely watching the sales performance of Mounjaro and Zepbound when Eli Lilly reports its second-quarter 2026 results alongside the first commercial read on Foundayo (orforglipron), which launched in April and receives its first full-quarter commercial update today. The headline machinery around Eli Lilly is loud, but the durable second-order read belongs one step removed — in the biosimulation and regulatory science infrastructure that every competing GLP-1 filer must now activate. Oral delivery, not just higher numbers, is now a primary axis of competition , which means a wave of new NDA filings and formulation optimization work is not a distant possibility but an imminent workflow burden across the industry. Certara sits precisely at that bottleneck: from molecule to market, Certara integrates science, technology, strategic and regulatory expertise, and navigates complex regulatory landscapes with AI-driven tools while reducing development risk through predictive science and model-informed strategies . Certara recently launched an expedited Pharmacometrics regulatory submission service that cuts submission timelines in half — a capability that is structurally more valuable in a race where multiple sponsors are filing oral and next-generation GLP-1 formulations concurrently than in any single-drug cycle.